Strides Pharma Q4 FY25 Earnings Results: Revenue Rose 17.2% and Delivers 12x PAT Growth

Strides Pharma Science Ltd has reported strong growth for the financial year ending March 31, 2025. The company performed well across all major financial indicators.

Strides Pharma Science Ltd delivered a strong performance in FY2025, with revenue rising to ₹45,653 crore, marking a 17.2% increase from the previous year. The company's gross profit also saw a significant rise of 20.5% year-on-year, reaching ₹25,854 crore. EBITDA grew by 36.8% to ₹8,028 crore, while the EBITDA margin improved by 252 basis points to 17.6%, reflecting enhanced operational efficiency. 

The company’s US market revenue climbed to $291 million, registering a robust growth of 21.8%. Operational profit after tax (PAT) saw a remarkable 12-fold jump to ₹3,447 crore, and operational earnings per share (EPS) mirrored this growth, increasing 12 times to ₹37.5.

Q4FY25 Highlights (January to March 2025)

The company also ended the final quarter on a high note with strong quarterly growth.

• Quarterly revenue stood at ₹11,904 crore, up 17% YoY.
• Gross profit for Q4 was ₹6,914 crore, an 18.1% increase.
• EBITDA rose by 22% to ₹2,179 crore, with EBITDA margin improving to 18.3%.
• US revenue in Q4 reached $77 million, a 23.2% increase over last year.
• Operational PAT increased five times to ₹1,130 crore.
• Operational EPS also grew five times to ₹12.3.

Quarter-on-Quarter Performance (Q3FY25 vs Q4FY25)

• Revenue rose 3.2% from the previous quarter.
• EBITDA increased by 3.6%.
• Operational PAT grew 22% compared to Q3FY25.

Also Read: IndusInd Bank to Realign Senior Management Roles After Accounting Review! 

About Strides Pharma

Strides Pharma Science mainly operates in regulated international markets. It also has a strong presence in Africa with a focus on local operations ("in Africa for Africa") and serves donor-funded institutions.

As of May 22 at 2:06 PM IST, Strides Pharma Science share price is trading at ₹712.05, up ₹16.50 or 2.37% for the day. The stock opened at ₹690.10 and has touched an intraday high of ₹717.00 and a low of ₹680.00. The company has a market capitalisation of ₹6,560 crore, a price-to-earnings (P/E) ratio of 24.32, and offers a dividend yield of 0.35%. Over the past 52 weeks, the stock has traded between a low of ₹329.86 and a high of ₹804.00.

Conclusion

Strides Pharma's FY25 performance reflects strong execution and global market traction, especially in the US. With solid margin gains and strategic presence across key geographies, the company is well-positioned for sustained growth in FY26 and beyond.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.                  

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.